Another TCR therapy, letetresgene autoleucel (“lete-cel”) targeting HLA-A*02 restricted NY-ESO1, found an ORR of 40% in the IGNYTE-ESO (NCT03967223) phase II trial of patients with synovial sarcoma and myxoid round cell liposarcoma [170]. The gene discussed is HLA-A; the disease is synovial sarcoma.